{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 163,
  "pageCount": 239,
  "prevPage": 162,
  "nextPage": 164,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Uses multiple pull-quotes from KOLs to build a case against the company's clinical trial integrity.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/163",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-163",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Everyone again feels that Nevro just cherry-picked their PDN study because diabetics are notoriously not compliant. That's why they have diabetes to begin with. And Nevro cherry-picks picture-perfect diabetic patients that always take the medication, their A1C was always below 7 and that's not realistic. That's not the average American that eats hoagies in Philadelphia.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b344-cfe0ddee70dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.88,
        "x": 0.06,
        "y": 0.56
      },
      "kind": "list",
      "text": "A KOL stated that the ethics of the study design and exclusion criteria were \"questionable\" and thar the study \"lacks robustness.\"",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d42aa56-9c35-452b-9f7e-3c19a8dbbed4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.88,
        "x": 0.06,
        "y": 0.41
      },
      "kind": "list",
      "text": "Another KOL stated that Nevro's exclusion criteria would cause him to reject 85-90% of diabetic stimulator candidates he sees",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50b6e6cf-ba13-434e-a57f-ed9d28fe236b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.88,
        "x": 0.06,
        "y": 0.23
      },
      "kind": "list",
      "text": "A KOL and speaker who teaches/meets with scores of implanters states that \"everyone again\" thinks Nevro cherry-picked study patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d508ad18-c901-434b-b2c2-3098de8c338f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.88,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Specifically, KOL's slammed the PDN study's cherry-picking of diabetic patients, implying the exclusion criteria reflected an unethical study design. The criticism was identical to that of the SENZA pivotal trial: enrolling patients that are not representative of the real world. One indicated the PDN study \"is just as bad as their original SENZA\" trial and \"lacks robustness.\"",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6dbfb405-d7a1-4f8f-8d95-1cea3726c09b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.83,
        "x": 0.11,
        "y": 0.28
      },
      "kind": "quote",
      "text": "\"Everyone again feels that Nevro just cherry-picked their PDN study because diabetics are notoriously not compliant. That's why they have diabetes to begin with. And Nevro cherry-picks picture-perfect diabetic patients that always take the medication, their A1C was always below 7 and that's not realistic. That's not the average American that eats hoagies in Philadelphia.\" – KOL and speaker",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "031152ef-0c46-4b3b-9f2b-dc646b46fcb4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.83,
        "x": 0.11,
        "y": 0.61
      },
      "kind": "quote",
      "text": "\"Nevro's trying to put a sexy spin on a therapy that we've already been using forever. The ethics of their study design is questionable, like their exclusion criteria. They're going to have a lot of explants. They don't have the waveform capabilities that other companies have. The diabetic peripheral neuropathy study is just as bad as their original Senza study. It lacks robustness. It's not a level-one study.\" - KOL",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "239af0ab-7219-463f-8378-7b3fd0494afa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.83,
        "x": 0.11,
        "y": 0.46
      },
      "kind": "quote",
      "text": "\"If I used these exclusion criteria in my own population of diabetic patients, I could maybe enroll 10% or 15% of them. It was a vast list of exclusion criteria. That study doesn't reflect real-world outcomes. It used the best of the best of the best patients.\" – KOL and high volume implanter",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5165f32-19fa-4f2c-99d2-4285092724e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“Everyone again feels that Nevro just cherry-picked their PDN study because diabetics are notoriously not compliant. That's why they have diabetes to begin with. And Nevro cherry-picks picture-perfect diabetic patients that always take the medication, their A1C was always below 7 and that's not realistic. That's not the average American that eats hoagies in Philadelphia.” — KOL and speaker; “If I used these exclusion criteria in my own population of diabetic patients, I could maybe enroll 10% or 15% of them. It was a vast list of exclusion criteria. That study doesn't reflect real-world outcomes. It used the best of the best of the best patients.” — KOL and high volume implanter; “Nevro's trying to put a sexy spin on a therapy that we've already been using forever. The ethics of their study design is questionable, like their exclusion criteria. They're going to have a lot of explants. They don't have the waveform capabilities that other companies have. The diabetic peripheral neuropathy study is just as bad as their original Senza study. It lacks robustness. It's not a level-one study.” — KOL",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b344-d15766fc34f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c0c1531-9142-4496-9e75-781080cb76ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "title",
      "text": "11. TAM expansion and growth from painful diabetic neuropathy (PDN) and other new indications are a mirage",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed06b47d-9529-4ab8-94ae-65105937148f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b8049de-2fdc-430d-9b2a-7ee2e66d8086",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "f1af12d2-dc6b-4e81-91cd-ecb3d7027775",
      "evidence": "Uses KOL quotes to validate claims",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}